BenevolentAI Share Price

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 15:08:14 24/05/2024 BST 5-day change 1st Jan Change
0.576 EUR -4.00% Intraday chart for BenevolentAI +0.70% -46.67%

Financials

Sales 2024 * 33.62M 42.82M 39.46M 3.36B Sales 2025 * 31.32M 39.89M 36.76M 3.13B Capitalization 59.81M 76.18M 70.2M 5.98B
Net income 2024 * -8M -10.19M -9.39M -800M Net income 2025 * -14M -17.83M -16.43M -1.4B EV / Sales 2024 * 0.65 x
Net cash position 2024 * 37.88M 48.24M 44.46M 3.79B Net cash position 2025 * 103M 132M 121M 10.34B EV / Sales 2025 * -1.39 x
P/E ratio 2024 *
-9.9 x
P/E ratio 2025 *
-7.61 x
Employees 248
Yield 2024 *
-
Yield 2025 *
-
Free-Float 53.04%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.00%
1 week+0.70%
Current month-10.00%
1 month-21.10%
3 months-24.21%
6 months-12.73%
Current year-46.67%
More quotes
1 week
0.56
Extreme 0.562
0.63
1 month
0.54
Extreme 0.54
0.68
Current year
0.54
Extreme 0.54
1.41
1 year
0.48
Extreme 0.48
2.66
3 years
0.48
Extreme 0.48
10.00
5 years
0.48
Extreme 0.48
10.00
10 years
0.48
Extreme 0.48
10.00
More quotes
Managers TitleAgeSince
Founder 48 31/10/13
Director of Finance/CFO - 10/09/23
Chief Tech/Sci/R&D Officer - 30/06/20
Members of the board TitleAgeSince
Director/Board Member 68 30/06/20
Director/Board Member 60 21/04/22
Director/Board Member 66 31/08/21
More insiders
Date Price Change Volume
24/05/24 0.576 -4.00% 5,833
23/05/24 0.6 -1.64% 3,953
22/05/24 0.61 -1.61% 6,641
21/05/24 0.62 +5.08% 15,518
20/05/24 0.59 +3.15% 27,410

Real-time Euronext Amsterdam, May 24, 2024 at 03:08 pm

More quotes
BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4905 GBP
Average target price
1.935 GBP
Spread / Average Target
+294.49%
Consensus

Quarterly revenue - Rate of surprise